SecBot SecBot
SECBOTREPLAY Home › Report › OSUR

OSUR · OraSure Technologies reported a significant decline in Q4 and full-year…

ORASURE TECHNOLOGIES INC · 8-K filed Feb 25, 2026 at 16:13 ET

At the news

MIXEDIMPACT 6/10

8-K filed Feb 25, 2026 at 16:13 ET

OraSure Technologies reported a significant decline in Q4 and full-year 2025 revenue, down 29% and 38% respectively, driven by steep drops in its core diagnostics and sample management businesses. Despite the poor financial performance, the company highlighted new FDA submissions for a Chlamydia/Gonorrhea self-test and a urine collection device, and maintained a $40 million share buyback program. The filing presents a mixed picture of deteriorating fundamentals offset by future growth initiatives.

  • Q4 2025 revenue was $26.8 million, down 29% YoY; full-year revenue was $115 million, down 38% YoY.
  • Core business revenue (excluding COVID-19) declined 22% YoY in Q4 and 14% for the full year.
  • GAAP net loss was $19.3 million for Q4 and $68.7 million for the full year.
  • Company submitted two new applications to the FDA in December 2025 for a rapid molecular self-test for Chlamydia/Gonorrhea and a Colli-Pee at-home urine collection device.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access